{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:25:17Z","timestamp":1772472317070,"version":"3.50.1"},"reference-count":27,"publisher":"CSIRO Publishing","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":2079,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Previous Australian research has shown that following the 21% increase in patient copayments for medications on the Pharmaceutical Benefits Scheme (PBS) in 2005, the use of lipid-lowering therapy declined by 5%. This study aimed to determine the demographic and clinical characteristics of individuals who continued, reduced or ceased their use of statin medication in 2005.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study type:<\/jats:title>\n                    <jats:p>Retrospective observational study using routinely collected administrative data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>We used pharmaceutical claims, hospital separations and mortality records from 2000 to 2005 for the Western Australian population. The cohort comprised stable users of statin medication in 2004. Based on changes in statin use between 2004 and 2005, we identified individuals who: 1) continued using statins; 2) reduced their use by \u226520%; or 3) ceased therapy for at least the first 6 months in 2005. Multivariate logistic regression models were used to determine whether the demographic and clinical characteristics of the three groups differed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There were 205 924 statin users identified in Western Australia as of December 2004. After the January 2005 Pharmaceutical Benefits Scheme (PBS) copayment increase, 3.2% of users ceased their regular statin therapy, 12.9% reduced statin use and 83.9% continued statin use. This represented a 2.1% increase in statin users reducing or ceasing therapy compared to 2004. Predictors of cessation and reduction of statin therapy included younger age, greater socio-economic disadvantage, residing in very remote areas, having general beneficiary status, being a new statin user, having no prior history of ischaemic heart disease, having no prior history of a coronary artery revascularisation procedure, taking no other cardiovascular medication or diabetic medication, taking an increased number of medications, and having a lower level of adherence to statin medication in 2004.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Compared to 2004, an additional 2.1% of statin users reduced or discontinued medication use in 2005, which may be attributed to an increase in the medication copayment. Individuals with general beneficiary status, and younger and healthier people were at particular risk of cessation or reduction in statin use in 2005.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.17061\/phrp29121905","type":"journal-article","created":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T19:46:57Z","timestamp":1556740017000},"source":"Crossref","is-referenced-by-count":9,"title":["Predictors of ceasing or reducing statin medication following a large increase in the consumer copayment for medications: a retrospective observational study"],"prefix":"10.1071","volume":"30","author":[{"given":"Karla","family":"Seaman","sequence":"first","affiliation":[{"name":"A School of Health Sciences, University of Notre Dame, Perth, WA, Australia"},{"name":"B School of Nursing and Midwifery, Edith Cowan University, Perth, WA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Sanfilippo","sequence":"additional","affiliation":[{"name":"C Cardiovascular Research Group, School of Population and Global Health, University of Western Australia, Perth"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Bulsara","sequence":"additional","affiliation":[{"name":"D Institute for Health Research, University of Notre Dame, Perth, WA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libby","family":"Roughead","sequence":"additional","affiliation":[{"name":"E Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kemp-Casey","sequence":"additional","affiliation":[{"name":"F Centre for Health Services Research, School of Population and Global Health, University of Western Australia, Perth"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Bulsara","sequence":"additional","affiliation":[{"name":"A School of Health Sciences, University of Notre Dame, Perth, WA, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Watts","sequence":"additional","affiliation":[{"name":"G Lipid Disorders Clinic, Department of Cardiology, Royal Perth Hospital, WA, Australia"},{"name":"H School of Medicine and Pharmacology, University of Western Australia, Perth"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Preen","sequence":"additional","affiliation":[{"name":"F Centre for Health Services Research, School of Population and Global Health, University of Western Australia, Perth"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2020,3,10]]},"reference":[{"key":"2026012719561583300_R1","doi-asserted-by":"crossref","unstructured":"Schoen C, Osborn R, Squires D, Doty MM, Pierson R, Applebaum S. How health insurance design affects access to care and costs, by income, in eleven countries. Health Aff. 2010;29(12):2323\u201334. CrossRef | PubMed","DOI":"10.1377\/hlthaff.2010.0862"},{"key":"2026012719561583300_R2","unstructured":"Australian Government Department of Health. PBS: The Pharmaceutical Benefits Scheme. Canberra: Commonwealth of Australia; 2019. About the PBS [cited 2017 Dec 1]; [about 3 screens]. Available from: www.pbs.gov.au\/info\/about-the-pbs"},{"key":"2026012719561583300_R3","doi-asserted-by":"crossref","unstructured":"Hynd A, Roughead EE, Preen DB, Glover J, Bulsara MK, Semmens J. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia. Pharmacoepidemiol Drug Saf. 2008;17(11):1091\u20139. CrossRef | PubMed","DOI":"10.1002\/pds.1670"},{"key":"2026012719561583300_R4","doi-asserted-by":"crossref","unstructured":"McManus P, Donnelly N, Henry D, Hall W, Primrose J, Lindner J. Prescription drug utilization following patient co-payment changes in Australia. Pharmacoepidemiol Drug Saf. 1996;5(6):385\u201392. CrossRef | PubMed","DOI":"10.1002\/(SICI)1099-1557(199611)5:6<385::AID-PDS246>3.3.CO;2-#"},{"key":"2026012719561583300_R5","doi-asserted-by":"crossref","unstructured":"Tamblyn R, Laprise R, Hanley JA, Abrahamowicz M, Scott S, Mayo N, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA. 2001;285(4):421\u20139. CrossRef | PubMed","DOI":"10.1001\/jama.285.4.421"},{"key":"2026012719561583300_R6","doi-asserted-by":"crossref","unstructured":"Hynd A, Roughead EE, Preen DB, Glover J, Bulsara M, Semmens J. Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia. Aust N Z J Public Health. 2009;33(3):246\u201352. CrossRef | PubMed","DOI":"10.1111\/j.1753-6405.2009.00383.x"},{"key":"2026012719561583300_R7","doi-asserted-by":"crossref","unstructured":"Schaffer AL, Buckley NA, Dobbins TA, Banks E, Pearson S-A. The crux of the matter: did the ABC\u2019s Catalyst program change statin use in Australia? Med J Aust. 2015;202(11):591\u20135. CrossRef | PubMed","DOI":"10.5694\/mja15.00103"},{"key":"2026012719561583300_R8","unstructured":"Australian Government Department of Health. PBS: The Pharmaceutical Benefits Scheme. Canberra: Commonwealth of Australia; 2017. Supplying medicines \u2013 what pharmacists need to know [cited 2017 Dec 1]; [about 4 screens]. Available from: www.pbs.gov.au\/info\/healthpro\/explanatory-notes\/section1\/Section_1_3_Explanatory_Notes"},{"key":"2026012719561583300_R9","doi-asserted-by":"crossref","unstructured":"Donnelly N, McManus P, Dudley J, Hall W. Impact of increasing the re-supply interval on the seasonality of subsidised prescription use in Australia. Aust N Z J Public Health. 2000;24(6):603\u20136. CrossRef | PubMed","DOI":"10.1111\/j.1467-842X.2000.tb00524.x"},{"key":"2026012719561583300_R10","doi-asserted-by":"crossref","unstructured":"Seaman KL, Sanfilippo FM, Roughead EE, Bulsara MK, Kemp-Casey A, Bulsara C, et al. Impact of consumer copayments for subsidised medicines on health services use and outcomes: a protocol using linked administrative data from Western Australia. BMJ Open. 2017;7(6):e013691. CrossRef | PubMed","DOI":"10.1136\/bmjopen-2016-013691"},{"key":"2026012719561583300_R11","doi-asserted-by":"crossref","unstructured":"Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15(8):565\u201374. CrossRef | PubMed","DOI":"10.1002\/pds.1230"},{"key":"2026012719561583300_R12","unstructured":"Australian Bureau of Statistics. Census of population and housing: Socio-Economic Indexes for Areas (SEIFA), Australia 2016. Canberra: ABS; 2013 [cited 2017 Dec 1]. Available from: www.abs.gov.au\/ausstats\/abs@.nsf\/mf\/2033.0.55.001\/"},{"key":"2026012719561583300_R13","unstructured":"Australian Government Department of Health. Accessibility Remoteness Index of Australia (ARIA) Remoteness Area (RA). Canberra: Commonwealth of Australia; 2018 [cited 2019 Mar 12]; [about 3 screens]. Available from: www.health.gov.au\/internet\/publications\/publishing.nsf\/Content\/ARIA-Review-Report-2011~ARIA-Review-Report-2011-2~ARIA-Review-Report-2011-2-2-3"},{"key":"2026012719561583300_R14","unstructured":"WHO Collaborating Centre for Dug Statistics Methodology. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2013. Cardiovascular system [cited 2017 Sep 13]; [about 2 screens]. Available from: www.whocc.no\/atc_ddd_index\/?code=C&showdescription=yes"},{"key":"2026012719561583300_R15","unstructured":"WHO Collaborating Centre for Dug Statistics Methodology. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2016. A10 drugs used in diabetes [cited 2017 Sep 13]; [about 1 screen]. Available from: www.whocc.no\/atc_ddd_index\/?code=A10"},{"key":"2026012719561583300_R16","unstructured":"Australian Consortium for Classification Development. The international statistical classification of diseases and related health problems, tenth revision, Australian modification (ICD-10-AM\/ACHI\/ACS): ninth edition. Sydney: Independent Hospital Pricing Authority; 2015 [cited 2019 Apr 29]. Available from: www.accd.net.au\/Icd10.aspx?page=2"},{"key":"2026012719561583300_R17","unstructured":"Australian Consortium for Classification Development. The international statistical classification of diseases and related health problems, tenth revision, Australian modification (ICD-10-AM\/ACHI\/ACS): tenth edition. Sydney: Independent Hospital Pricing Authority; 2017 [cited 2019 Apr 29]. Available from: www.accd.net.au\/Icd10.aspx?page=3"},{"key":"2026012719561583300_R18","doi-asserted-by":"crossref","unstructured":"Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208\u201315. CrossRef | PubMed","DOI":"10.1016\/j.jacl.2012.03.003"},{"key":"2026012719561583300_R19","doi-asserted-by":"crossref","unstructured":"Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940\u20138. CrossRef | PubMed","DOI":"10.1093\/eurheartj\/eht295"},{"key":"2026012719561583300_R20","doi-asserted-by":"crossref","unstructured":"Warren JR, Falster MO, Fox D, Jorm L. Factors influencing adherence in long-term use of statins. Pharmacoepidemiol Drug Saf. 2013;22(12):1298\u2013307. CrossRef | PubMed","DOI":"10.1002\/pds.3526"},{"key":"2026012719561583300_R21","doi-asserted-by":"crossref","unstructured":"Kemp A, Roughead E, Preen D, Glover J, Semmens J. Determinants of self-reported medicine underuse due to cost: a comparison of seven countries. J Health Serv Res Policy. 2010;5(2):106\u201314. CrossRef | PubMed","DOI":"10.1258\/jhsrp.2009.009059"},{"key":"2026012719561583300_R22","doi-asserted-by":"crossref","unstructured":"Kemp A, Glover J, Preen DB, Bulsara M, Semmens J, Roughead EE. From the city to the bush: increases in patient co-payments for medicines have impacted on medicine use across Australia. Aust Health Rev. 2013;37(1):4\u201310. CrossRef | PubMed","DOI":"10.1071\/AH11129"},{"key":"2026012719561583300_R23","unstructured":"Menzies Centre for Health Policy and Nous Group. Survey of attitudes towards the Australian health system part 2: financial stress and health. Sydney: Menzies Centre for Health Policy; 2009 [cited 7 Mar 2017]. Available from: ses.library.usyd.edu.au\/bitstream\/2123\/19909\/2\/2008surveyfinancialsummary.pdf"},{"key":"2026012719561583300_R24","unstructured":"Kemp A. Consumer co-payments for medicines: impact on use and the role of the pharmacist. Australian Pharmacist. 2010;29(9):747\u20138. Article"},{"key":"2026012719561583300_R25","unstructured":"Payne A. Working poor in Australia: an analysis of poverty among families in which a member is employed. Family Matters. 2009;81:15\u201324. Article"},{"key":"2026012719561583300_R26","unstructured":"Kemp A, Preen D, Sanfilippo F, Glover J, Semmens J, Roughead E. Evaluating pharmaceutical policy impact using interrupted time series analysis: an Australian case study. Int Public Health J. 2011;3(2):229\u201341. Article"},{"key":"2026012719561583300_R27","doi-asserted-by":"crossref","unstructured":"Clark A, Preen DB, Ng JQ, Semmens JB, Holman D. Is Western Australia representative of other Australian States and Territories in terms of key socio-demographic and health economic indicators? Aust Health Rev. 2010; 34(2):210\u201315. CrossRef | PubMed","DOI":"10.1071\/AH09805"}],"container-title":["Public Health Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/pu\/article-pdf\/doi\/10.17061\/phrp29121905\/1821627\/pu19253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/pu\/article-pdf\/doi\/10.17061\/phrp29121905\/1821627\/pu19253.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:56:23Z","timestamp":1769561783000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/pu\/article\/30\/1\/e29121905\/265266\/Predictors-of-ceasing-or-reducing-statin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3,10]]}},"URL":"https:\/\/doi.org\/10.17061\/phrp29121905","relation":{},"ISSN":["2204-2091"],"issn-type":[{"value":"2204-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,10]]},"article-number":"e29121905"}}